GSK said on Friday the addition of its cancer drug Jemperli to both standard of care chemotherapy and Zejula maintenance ...

Goldman Sachs analyst Rajan Sharma maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) yesterday and set a price target of ...

In one of the final steps before a marketing authorization decision by the European Medicines Agency, it recommended ...

First approved in 2021, Jemperli has now become a cornerstone of GSK’s cancer business, earning more than $160 million in the ...

Bank of America Securities analyst Graham Parry has maintained their bearish stance on GSK stock, giving a Sell rating on December 11.Pick the ...

GSK has handed over $45 million upfront to fellow London-based firm Relation to help the pharma identify new targets for ...

UK pharma major GSK today released mixed headline results from the FIRST-ENGOT-OV44 Phase III trial evaluating Zejula ...

Relation Therapeutics and GSK signed two contracts to discover and develop new therapeutic targets to treat osteoarthritis and fibrotic disease.

Relation has announced two strategic collaborations with GSK, focusing on new therapeutics for fibrotic and osteoarthritis.

(Alliance News) - GSK ... based pharmaceuticals firm said jemperli, the brand name of dostarlimab, plus chemotherapy has received a positive opinion from the Committee for Medicinal Products ...

Big pharma company GSK and UK AI-biotech Relation Therapeutics have entered into two strategic collaborations to identify and ...

GSK's cancer drug Jemperli cleared an important hurdle ahead of potentially expanding its European Union marketing permission, in a boost to the pharmaceutical giant's oncology pipeline.